NHS rolls out ‘COVID-friendly’ cancer treatments

NHS chief executive, Sir Simon Stevens has announced the roll-out of ‘COVID-friendly’ cancer treatments that are safer for patients during the pandemic. The treatments will be expanded and extended through a £160 million NHS initiative. The funding will be used to pay for drugs that do not have a big effect on the immune system […]

read more

The impact of COVID-19 pandemic on treatment for metastatic kidney cancer

A recent online survey involving 41 kidney cancer experts worldwide looked at the changes made to their clinical practice for the treatment of metastatic renal cell carcinoma (RCC) during the COVID-19 pandemic. The majority of the experts prescribed immunotherapy combination treatment for untreated metastatic RCC patients. The survey showed an increase in the use of […]

read more

NHS accelerates the launch of stereotactic ablative radiotherapy

  In order to offer more convenient and potentially safer forms of cancer treatment as a result of the coronavirus pandemic, NHS England is accelerating the launch of a new type of radiotherapy.  Stereotactic ablative radiotherapy (SABR) is a very precise method of radiotherapy that uses fewer doses of radiation than conventional radiotherapy, thus cutting […]

read more

IKCS 2019: Management of small renal masses

In this video interview, Dr Eric Singer from Rutgers Cancer Institute of New Jersey, USA discusses the management of small renal masses at the International Kidney Cancer Symposium (IKCS) in Miami earlier this month. Watch the video interview on Oncology Tube here

read more

Kidney cancer experts talk about the latest advances in treatments

The following interviews with kidney cancer experts discuss the latest advances in the treatment of renal cell carcinoma (RCC) and renal masses: No OS signal in axitinib + avelumab combination therapy – Dr Toni Choueiri, Dana Faber Cancer Institute, Boston, USA Treating renal masses with minimal invasive ablative technique – Dr Alessandro Volpe, Maggiore Della […]

read more

New cancer drug payment system could speed up access to treatments

Cancer Research UK and the Greater Manchester Health and Social Care Partnership has produced a report suggesting a new system for reimbursement of cancer drugs by the NHS. The report suggests that paying for cancer drugs based on how well they work in practice could help patients get new treatments faster. This new flexible system, […]

read more

‘Mini-tumours’ to help predict response to cancer treatments

A new study, published in the journal Science last week, shows how miniture versions of tumours can be grown in the laboratory and used to predict which drugs would be effective in patients. The study was 100% accurate at telling which drugs would fail and could spare patients from unnecessary side effects of these drugs. […]

read more

First-line immunotherapy for metastatic kidney cancer

The following is a Practice Update interview with Dr Eric Jonasch, Professor of genitourinary medical oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. During this interview, Dr Jonasch talks about the upcoming immunotherapy combinations for use in the first-line for the treatment of metastatic renal cell carcinoma (mRCC), as well as […]

read more

Combination immunotherapy: the new standard of care for metastatic kidney cancer

The following video interviews discuss combinations of immunotherapy drugs and immunotherapy plus targeted therapy for the first-line treatment of metastatic renal cell carcinoma (RCC). Sumanta K. Pal, MD, of the City of Hope National Medical Center in California, USA discusses immunotherapy as a first-line treatment for kidney cancer and the strategy of VEGF blockade with […]

read more
Showing 1 to 10 of 25 results
  TOP